Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
biropepimut-S (GL-0817)
i
Other names:
GL-0817, MAGE-A3 vaccine
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
News
Trials
Company:
Gliknik, University of Pennsylvania
Drug class:
MAGE-A3 modulator
Related drugs:
‹
MAGE-A3 vaccine (2)
KITE-718 (0)
MAGE A3 TCR (0)
VTP-600 (0)
astuprotimut-R (0)
MAGE-A3 vaccine (2)
KITE-718 (0)
MAGE A3 TCR (0)
VTP-600 (0)
astuprotimut-R (0)
›
Associations
News
Trials
Filter by
Latest
over2years
Safety and Efficacy Study of GL-0817 (With Cyclophosphamide) for the Prevention of Recurrence of Squamous Cell Carcinoma of the Oral Cavity (clinicaltrials.gov)
P2, N=80, Completed, Gliknik Inc. | Active, not recruiting --> Completed
over 2 years ago
Trial completion
|
MAGEA3 (MAGE Family Member A3)
|
cyclophosphamide • Hiltonol (poly-ICLC) • Leukine (sargramostim) • biropepimut-S (GL-0817)
Share via
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login